Platelet Carbonic Anhydrase II, a Forgotten Enzyme, May Be Responsible for Aspirin Resistance

Abstract EN

Background.

Thromboembolic events constitute a major health problem, despite the steadily expanding arsenal of antiplatelet drugs.

Hence, there is still a need to optimize the antiplatelet therapy.

Objectives.

The aim of our study was to verify a hypothesis that there are no differences in platelet proteome between two groups of healthy people representing different acetylsalicylic acid (aspirin) responses as assessed by the liquid chromatography/mass spectrometry (LC/MS) technique.

Patients/Methods.

A total of 61 healthy volunteers were recruited for the study.

Physical examination and blood collection were followed by platelet-rich plasma aggregation assays and platelet separation for proteomic LC/MS analysis.

Arachidonic acid- (AA-) induced aggregation (in the presence of aspirin) allowed to divide study participants into two groups aspirin-resistant (AR) and aspirin-sensitive (AS) ones.

Subsequently, platelet proteome was compared in groups using the LC/MS analysis.

Results.

The LC/MS analysis of platelet proteome between groups revealed that out of all identified proteins, the only discriminatory protein, affecting aspirin responsiveness, is platelet carbonic anhydrase II (CA II).

Conclusions.

CA II is a platelet function modulator and should be taken into consideration as a cardiovascular event risk factor or therapeutic target.